NATCO Pharma Ltd. moves to reshape its capital structure

The proceeds allocation cannot be stated precisely from the filing extract available here. The exchange disclosure confirms a rights issue of up to Rs 1,300 Crores through fully paid equity shares, but the cited extract does not set out a split between debt repayment, capex, acquisitions, working capital or other uses ^[1]. Consequently, the post-issue leverage and interest-coverage outcomes depend on how the funds are deployed.

Current consolidated position: Q1 FY27

• Net debt: Rs 507.50 Crores ^[2]
• Total debt: Rs 706.40 Crores ^[3]
• Cash and equivalents: Rs 198.90 Crores ^[4]
• Interest coverage: 18.90x for Q1 FY27 ^[5]
• TTM interest coverage: 24.75x ^[6]

Balance-sheet impact under the relevant scenarios

• If the full Rs 1,300 Crores is retained as cash or applied entirely to debt repayment: net debt would move from Rs 507.50 Crores to approximately negative Rs 792.50 Crores, i.e. net cash of Rs 792.50 Crores. This is a derived maximum-impact scenario using the approved issue size ^[1] and current net debt ^[2]. It assumes full subscription, no issue costs and no intervening balance-sheet changes.
• If the proceeds fund capex, acquisitions or other operating uses: net debt may not reduce materially; cash would be converted into assets or deployed cash, while debt could remain at the current level.
• Interest coverage: the rights issue itself does not increase EBIT or reduce finance costs, so the reported coverage would initially remain anchored to 18.90x quarterly or 24.75x TTM ^{[5] [6]}. If proceeds are used to repay interest-bearing debt, finance costs should decline and coverage should improve, but the post-issue ratio cannot be quantified without the allocation, repayment timing and interest rates. If the proceeds are invested in growth assets, the benefit to coverage would depend on the earnings generated.

Bottom line: the equity raise creates up to Rs 1,300 Crores of balance-sheet flexibility, but it is not possible to conclude that Natco’s net debt will fall—or to calculate a new interest-coverage ratio—until the filing’s objects-of-the-issue allocation and actual deployment are disclosed.

The Demerger Scheme update does not provide enough information for a numerical pro-forma EBITDA-margin bridge between Agrochemicals and core Pharmaceuticals. It changes the transaction mechanics after the proposed rights issue—not the reported operating segmentation. The company has received exchange observation letters, but has not yet filed the Scheme with the NCLT; the Scheme will be revised after the rights issue to preserve the proposed share-swap ratio. ^[7]

Margin bridge

The required calculation is:

`Core pharma EBITDA margin = (Consolidated EBITDA – Agrochemicals EBITDA) / (Consolidated revenue – Agrochemicals revenue)`

Therefore, the impact depends on whether Agrochemicals operates above or below NATCO’s consolidated margin. Using the Q3 FY26 revenue mix only as a mechanical sensitivity, the change in core-pharma margin would be approximately:

`4% / 96% × (consolidated margin – Agrochemicals margin)`

That means a 10 percentage-point margin differential would change the continuing-pharma margin by roughly 0.42 percentage points, but the actual differential is not disclosed. This is not a Q1 FY27 pro-forma calculation because the 4% mix and the 33.4% consolidated margin relate to different periods.

The Q1 FY27 standalone EBITDA margin of 25.9% versus 33.4% on a consolidated basis cannot be used as the Agrochemicals adjustment: that gap reflects the different consolidation perimeter and other subsidiaries or businesses, not Agrochemicals alone. ^{[10] [13]}

Conclusion: the carve-out should have a limited revenue-mix effect based on disclosed figures, but the direction and magnitude of the EBITDA-margin change remain unquantified until NATCO reports Agrochemicals EBITDA, its standalone margin, and the treatment of shared corporate costs.

As of 9 September 2026, the demerger had not yet reached the NCLT-approval stage. The stock-exchange observation-letter milestone was complete, but the scheme now needs to be revised after the proposed rights issue and resubmitted before the NCLT process can proceed. ^[7]

Pending milestones

• Rights issue completion and scheme revision: The proposed rights issue will change Natco Pharma’s capital structure and shareholding pattern. Management therefore plans to revise the scheme, while preserving the existing share-swap ratio, and file the revised scheme with the stock exchanges after completion of the rights issue. ^[7]
• NCLT filing and sanction: The company had not yet filed the scheme or related applications with the NCLT as of 9 September 2026. NCLT sanction under Sections 230–232 remains pending. ^[7]
• Shareholder and creditor approvals: Approval or consent from the respective shareholders and creditors remains a condition to implementation of the scheme. ^[14]
• Registrar of Companies filing: Even after NCLT sanction, certified copies of the NCLT order must be filed with the Registrar of Companies; this filing is part of the conditions precedent for the scheme to become effective. ^[15]
• Listing process: The resulting company, Natco Crop Health Sciences, can apply for stock-exchange listing only after the scheme is implemented. ^[14]

Record date and listing timeline

Management has not stated a firm demerger record date or a definitive listing date in the latest regulatory update. The “record date” disclosed on 9 September relates to the proposed rights issue and is still to be determined and notified; it should not be confused with the demerger record date. ^[16]

The scheme’s appointed date is 1 October 2026, subject to the NCLT or another competent authority approving a different date. This is an accounting/legal scheme date, not a confirmed record date or listing date. ^[15]

The earlier public description indicated that the resulting company would seek listing after implementation, while secondary coverage referred to October 2026 as a likely overall timeline but explicitly made it dependent on NCLT and other stakeholder approvals. ^[12] Accordingly, the practical sequence remains: complete rights issue → revise and refile scheme → obtain shareholder, creditor and NCLT approvals → file the sanction order with the RoC → announce the demerger record date → implement and pursue listing. No management-confirmed date for the last two steps has been disclosed.